URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. p
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. patent expected to expire in July 2044 - Patent claims cover treatment of recurrent lg-ir-nmibc without turbt
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.